Alnylam Pharmaceuticals (ALNY) EBT Margin (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly EBT Margin of 18.99% for Q1 2026, up 2688.0% year-on-year from 0.68% in Q1 2025, and up 141.51% on a QoQ basis from 7.86% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of EBT Margin data on file, last reported at 18.99% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 2688.0% year-over-year to 18.99%; the trailing twelve-month figure through Mar 2026 stood at 12.9% (up 3063.0% YoY), and the FY2025 full-year result was 8.7%, up 2549.0% from the prior year.
- EBT Margin for Q1 2026 stood at 18.99%, up from 7.86% in the prior quarter.
- Across five years, EBT Margin topped out at 22.46% in Q3 2025 and bottomed at 153.59% in Q3 2022.
- The 5-year median for EBT Margin is 21.69% (2024), against an average of 37.24%.
- The widest annual swing landed in 2022, when EBT Margin plunged 4474 bps; it then soared 17367 bps in 2023.
- A 5-year view of EBT Margin shows it stood at 61.79% in 2022, then soared by 49 bps to 31.31% in 2023, then fell by 4 bps to 32.7% in 2024, then jumped by 124 bps to 7.86% in 2025, then soared by 142 bps to 18.99% in 2026.
- The last three EBT Margin figures came in at 18.99% (Q1 2026), 7.86% (Q4 2025), and 22.46% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.99% |
| Dec 31, 2025 | 7.86% |
| Sep 30, 2025 | 22.46% |
| Jun 30, 2025 | -4.57% |
| Mar 31, 2025 | -7.89% |
| Dec 31, 2024 | -32.70% |
| Sep 30, 2024 | -21.69% |
| Jun 30, 2024 | -1.69% |
| Mar 31, 2024 | -12.86% |
| Dec 31, 2023 | -31.31% |
| Sep 30, 2023 | 20.08% |
| Jun 30, 2023 | -86.03% |
| Mar 31, 2023 | -53.98% |
| Dec 31, 2022 | -61.79% |
| Sep 30, 2022 | -153.59% |
| Jun 30, 2022 | -122.18% |
| Mar 31, 2022 | -112.24% |
| Dec 31, 2021 | -100.68% |
| Sep 30, 2021 | -108.85% |
| Jun 30, 2021 | -85.39% |
| Mar 31, 2021 | -112.23% |
| Dec 31, 2020 | -148.93% |
| Sep 30, 2020 | -200.59% |
| Jun 30, 2020 | -171.12% |
| Mar 31, 2020 | -182.60% |
| Dec 31, 2019 | -385.85% |
| Sep 30, 2019 | -298.21% |
| Jun 30, 2019 | -488.71% |
| Mar 31, 2019 | -544.30% |
| Dec 31, 2018 | -1,003.57% |
| Sep 30, 2018 | -11,833.59% |
| Jun 30, 2018 | -546.63% |
| Mar 31, 2018 | -645.13% |
| Dec 31, 2017 | -375.03% |
| Sep 30, 2017 | -719.10% |
| Jun 30, 2017 | -743.28% |
| Mar 31, 2017 | -565.88% |
| Dec 31, 2016 | -648.76% |
| Sep 30, 2016 | -765.31% |
| Jun 30, 2016 | -1,034.89% |
| Mar 31, 2016 | -1,401.96% |
| Dec 31, 2015 | -1,201.44% |
| Sep 30, 2015 | -1,214.29% |
| Jun 30, 2015 | -821.55% |
| Mar 31, 2015 | -276.25% |
| Dec 31, 2014 | -181.02% |
| Sep 30, 2014 | -400.31% |
| Jun 30, 2014 | -608.49% |
| Mar 31, 2014 | -3,248.50% |
| Dec 31, 2013 | -270.45% |
| Sep 30, 2013 | -355.42% |
| Jun 30, 2013 | -242.35% |
| Mar 31, 2013 | -51.36% |
| Dec 31, 2012 | 513.71% |
| Sep 30, 2012 | -116.37% |
| Jun 30, 2012 | -62.04% |
| Mar 31, 2012 | -55.22% |
| Dec 31, 2011 | 211.09% |
| Sep 30, 2011 | -63.67% |
| Jun 30, 2011 | -67.06% |
| Mar 31, 2011 | -77.93% |
| Dec 31, 2010 | -30.69% |
| Sep 30, 2010 | -33.73% |
| Jun 30, 2010 | -55.83% |
| Mar 31, 2010 | -50.09% |
| Dec 31, 2009 | -30.91% |
| Sep 30, 2009 | -40.25% |
| Jun 30, 2009 | -88.59% |